Literature DB >> 16401403

Aminopyrimidinimino isatin analogues: design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties.

Dharmarajan Sriram1, Tanushree Ratan Bal, Perumal Yogeeswari.   

Abstract

PURPOSE: HIV is the most significant risk factor for many opportunistic infections such as tuberculosis, hepatitis, bacterial infections and others. In this paper, we describe an aminopyrimidinimino isatin lead compound as a novel non-nucleoside reverse transcriptase inhibitor with broad-spectrum chemotherapeutic properties for the effective treatment of AIDS and AIDS-related opportunistic infections.
METHODS: The synthesis of various aminopyrimidinimino isatin derivatives was achieved in two steps and evaluated for anti-HIV, anti-HCV, antimycobacterial and antibacterial activities.
RESULTS: Compound 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-(4'-amino-5'-trimethoxybenzylpyrimidin-2'-yl)imino-1'-isatinyl] methyl]N1-piperazinyl]-3-quinoline carboxylic acid (14) emerged as the most potent broad-spectrum chemotherapeutic agent active against HIV, HCV, M. tuberculosis and various pathogenic bacteria. Among the synthesized compounds compound 14 and 15 emerged as more promising broad-spectrum chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16401403

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  9 in total

1.  Synthesis and Antiviral Studies of Novel N-Sulphonamidomethyl piperazinyl Fluoroquinolones.

Authors:  P Selvam; P Rathore; S Karthikumar; K Velkumar; P Palanisamy; S Vijayalakhsmi; M Witvrouw
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

2.  A green four-component synthesis of zwitterionic alkyl/benzyl pyrazolyl barbiturates and their photophysical studies.

Authors:  Manisha Bihani; Pranjal P Bora; Ghanashyam Bez; Hassan Askari
Journal:  Mol Divers       Date:  2014-07-09       Impact factor: 2.943

Review 3.  Significance and biological importance of pyrimidine in the microbial world.

Authors:  Vinita Sharma; Nitin Chitranshi; Ajay Kumar Agarwal
Journal:  Int J Med Chem       Date:  2014-03-23

Review 4.  Isatin derivatives as broad-spectrum antiviral agents: the current landscape.

Authors:  Tilal Elsaman; Malik Suliman Mohamed; Eyman Mohamed Eltayib; Hatem A Abdel-Aziz; Abualgasim Elgaili Abdalla; Muhammad Usman Munir; Magdi Awadalla Mohamed
Journal:  Med Chem Res       Date:  2022-01-13       Impact factor: 2.351

5.  Synthesis and characterization of new Schiff bases derived from N (1)-substituted isatin with dithiooxamide and their Co(II), Ni(II), Cu(II), Pd(II), and Pt(IV) complexes.

Authors:  Ahlam J Abdul-Ghani; Asmaa M N Khaleel
Journal:  Bioinorg Chem Appl       Date:  2009-10-26       Impact factor: 7.778

6.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06

7.  Antiproliferative activity of novel isatinyl/indanyl nitrones (INs) as potential spin trapping agents of free radical intermediates.

Authors:  Loredana Maiuolo; Giordana Feriotto; Vincenzo Algieri; Monica Nardi; Beatrice Russo; Maria Luisa Di Gioia; Emilia Furia; Matteo Antonio Tallarida; Carlo Mischiati; Antonio De Nino
Journal:  Medchemcomm       Date:  2017-12-20       Impact factor: 3.597

8.  N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo.

Authors:  Liba Sebastian; Anita Desai; Madhusudana N Shampur; Yogeeswari Perumal; D Sriram; Ravi Vasanthapuram
Journal:  Virol J       Date:  2008-05-22       Impact factor: 4.099

9.  Synthesis, characterization, and antiviral activity of novel fluorinated isatin derivatives.

Authors:  Samir Y Abbas; Awatef A Farag; Yousry A Ammar; Abeer A Atrees; Aly F Mohamed; Ahmed A El-Henawy
Journal:  Monatsh Chem       Date:  2013-07-12       Impact factor: 1.451

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.